Maynard Um
-
-
-
-
-
-
-
Akebia expects Vafseo revenue growth resumption in Q1 2026
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) Reports Publication of U.S. Patient Data from Global Phase 3 Clinical Program
-
-
-
-
-
-
-
Piper Sandler on Akebia Therapeutics (AKBA): 'Continue to Like the Setup; Remain Buyers'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo for Patients on Dialysis
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

